🚀 VC round data is live in beta, check it out!
Sprint Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sprint Bioscience and similar public comparables like Veru, Imugene, INmune Bio, Prescient Therapeutics and more.
Sprint Bioscience Overview
About Sprint Bioscience
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
Founded
2009
HQ
Employees
40
Website
Sectors
Financials (LTM)
EV
$25M
Sprint Bioscience Financials
Sprint Bioscience reported last 12-month revenue of $16M and EBITDA of $8M.
In the same LTM period, Sprint Bioscience generated $8M in EBITDA and $8M in net income.
Revenue (LTM)
Sprint Bioscience P&L
In the most recent fiscal year, Sprint Bioscience reported revenue of $19M and EBITDA of $11M.
Sprint Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $16M | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $17M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $8M | XXX | $11M | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 59% | XXX | XXX | XXX |
| EBIT Margin | 52% | XXX | 58% | XXX | XXX | XXX |
| Net Profit | $8M | XXX | $10M | XXX | XXX | XXX |
| Net Margin | 50% | XXX | 55% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sprint Bioscience Stock Performance
Sprint Bioscience has current market cap of $39M, and enterprise value of $25M.
Market Cap Evolution
Sprint Bioscience's stock price is $0.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25M | $39M | 2.6% | XXX | XXX | XXX | $0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSprint Bioscience Valuation Multiples
Sprint Bioscience trades at 1.6x EV/Revenue multiple, and 3.0x EV/EBITDA.
EV / Revenue (LTM)
Sprint Bioscience Financial Valuation Multiples
As of April 18, 2026, Sprint Bioscience has market cap of $39M and EV of $25M.
Equity research analysts estimate Sprint Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sprint Bioscience has a P/E ratio of 4.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39M | XXX | $39M | XXX | XXX | XXX |
| EV (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 3.0x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBIT | 3.0x | XXX | 2.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.5x | XXX | XXX | XXX |
| P/E | 4.9x | XXX | 3.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sprint Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sprint Bioscience Margins & Growth Rates
Sprint Bioscience's revenue in the last 12 month declined by (31%).
Sprint Bioscience's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Sprint Bioscience's rule of 40 is (26%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sprint Bioscience's rule of X is (103%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sprint Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (31%) | XXX | (53%) | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Growth | (52%) | XXX | (80%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (26%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (103%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sprint Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sprint Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Veru | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| INmune Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sprint Bioscience M&A Activity
Sprint Bioscience acquired XXX companies to date.
Last acquisition by Sprint Bioscience was on XXXXXXXX, XXXXX. Sprint Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sprint Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSprint Bioscience Investment Activity
Sprint Bioscience invested in XXX companies to date.
Sprint Bioscience made its latest investment on XXXXXXXX, XXXXX. Sprint Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sprint Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sprint Bioscience
| When was Sprint Bioscience founded? | Sprint Bioscience was founded in 2009. |
| Where is Sprint Bioscience headquartered? | Sprint Bioscience is headquartered in Sweden. |
| How many employees does Sprint Bioscience have? | As of today, Sprint Bioscience has over 40 employees. |
| Is Sprint Bioscience publicly listed? | Yes, Sprint Bioscience is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Sprint Bioscience? | Sprint Bioscience trades under SPRINT ticker. |
| When did Sprint Bioscience go public? | Sprint Bioscience went public in 2014. |
| Who are competitors of Sprint Bioscience? | Sprint Bioscience main competitors are Veru, Imugene, INmune Bio, Prescient Therapeutics. |
| What is the current market cap of Sprint Bioscience? | Sprint Bioscience's current market cap is $39M. |
| What is the current revenue of Sprint Bioscience? | Sprint Bioscience's last 12 months revenue is $16M. |
| What is the current revenue growth of Sprint Bioscience? | Sprint Bioscience revenue growth (NTM/LTM) is (31%). |
| What is the current EV/Revenue multiple of Sprint Bioscience? | Current revenue multiple of Sprint Bioscience is 1.6x. |
| Is Sprint Bioscience profitable? | Yes, Sprint Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sprint Bioscience? | Sprint Bioscience's last 12 months EBITDA is $8M. |
| What is Sprint Bioscience's EBITDA margin? | Sprint Bioscience's last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of Sprint Bioscience? | Current EBITDA multiple of Sprint Bioscience is 3.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.